AMAG bought Lumara for $675 million in 2014. At the time, Lumara was developing Makena, the only approved drug for reducing the risk of preterm birth for women who previously delivered early. The deal called for an additional $350 million in milestone payments if Makena reached certain sales thresholds, according to the complaint.
Those milestones were an essential part of the merger, without which Lumara’s shareholders wouldn’t ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.